EICHOR
● Active Not Recruiting
Improving Physical Ability and Cellular Senescence Elimination in HIV
Condition: HIV · Frailty · Prefrail · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
About this study
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (25)
| University of California, Los Angeles CARE Center CRS (Site ID: 601) | Los Angeles, California, United States | — |
| UCSD Antiviral Research Center CRS (Site ID: 701) | San Diego, California, United States | — |
| University of California, San Francisco HIV/AIDS CRS (Site ID: 801) | San Francisco, California, United States | — |
| Harbor University of California Los Angeles Center CRS (Site ID: 603) | Torrance, California, United States | — |
| University of Colorado Hospital CRS (Site ID: 6101) | Aurora, Colorado, United States | — |
| Whitman-Walker Institute, Inc. CRS (Site ID: 31791) | Washington D.C., District of Columbia, United States | — |
| Northwestern University CRS (Site ID: 2701) | Chicago, Illinois, United States | — |
| Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101) | Boston, Massachusetts, United States | — |
| Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS (Site ID: 107) | Boston, Massachusetts, United States | — |
| Washington University Therapeutics (WT) CRS (Site ID: 2101) | St Louis, Missouri, United States | — |
| New Jersey Medical School Clinical Research Center CRS (Site ID: 31786) | Newark, New Jersey, United States | — |
| Weill Cornell Chelsea CRS (Site ID: 7804) | New York, New York, United States | — |
+ 13 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07144293